You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201791 - 201800 of 207699 results
  1. Destroying the HIV-1 provirus by utilizing components of the CRISPR/Cas system

    SBC: CELDARA MEDICAL, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to develop a plasmid-based therapy that will destroy the integrated HIV-1 DNA (HIV- 1 provirus) in infected cells. Current HIV-1 anti-retroviral therapy (ARV) consists of a cocktail of drugsthat blocks viral binding and replication, but does not destroy the HIV-1 provirus. In addition, ARV does not impact the large reservoir of laten ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Glycoengineered baculoviruses for the production of more efficacious influenza va

    SBC: Glycobac, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Vaccination significantly reduces morbidity and mortality caused by annual influenza epidemics. Traditionally, influenza vaccines have been manufactured using adapted influenza virus grown in eggs. However, this methodsuffers from inherent disadvantages such as slow production and allergenic egg proteins in the final product. To avoid these drawbacks, new vacci ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Non-invasive Diagnostic Platform Development for Celiac Disease Remission Status

    SBC: ADAPTIVE BIOTECHNOLOGIES CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): The purpose of this proposal is to adapt a technology that we have developed for monitoring residual disease in leukemia patients to monitor residual autoimmune disease in Celiac Disease patients. Celiac disease hasa significant burden on quality of life, as it is one of the most frequent autoimmune diseases, with an estimated prevalence of approximately 1% ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Engineering of a Novel CDN Nanoparticle Platform

    SBC: MOLECULAR EXPRESS, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): For many years, the use of protein and peptide antigens to induce specific immune responses has been an area of intense effort with the goal of developing improved vaccines. In principle, this approach is attractive because it has the potential to provide immunological specificity, tighter control of manufacturing processes, and elimination of most of the secon ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. A novel antisense therapeutic for treatment of Aspergillus fumigatus infections

    SBC: GUILD ASSOCIATES INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Guild proposes to develop an antisense oligomer-based antifungal effective against the human pathogen Aspergillus fumigatus. With a 40%-60% mortality rate, invasive aspergillosis (IA) due to A. fumigatus now surpasses invasive candidiasis as the most frequent fungal cause of death, especially amongst immunocompromised patients. Successful therapy for IA with cu ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Novel system for sensitive detection of botulinum neurotoxins

    SBC: ALPHA UNIVERSE LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The existence of terrorist organizations around the world, along with their ability to recruit expertise from physicians and scientists, poses an increasing threat of bioterrorist attack to society. In order to reduce the consequences of such an attack or even prevent it, new systems for detection of biothreat agents are necessary. Currently existing express ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Algae-expressed colostrum protein as prophylaxis for enterotoxigenic E. coli

    SBC: TRITON ALGAE INNOVATIONS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Enterotoxigenic E. coli (ETEC) is the leading cause of diarrheal disease among children less than three years of age in developing countries and in travelers to these areas, with over 200 million cases annually, and 380,000 associated deaths. ETEC is transmitted by food or water contaminated with feces, and illness is characterized by profuse watery diarrhea la ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Discovering a Targeted Inositol Phosphorylceramide Synthase Inhibitor to Improve

    SBC: Amplyx Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Cryptococcal meningitis (CM) is the AIDS-defining illness for 60-70% of HIV positive individuals with an estimated worldwide occurrence of 1 million cases annually. CM is invariably fatal if left untreated, In sub-Saharan Africa alone, CM causes over 500,000 annual deaths among HIV positive patients compared with 350,000 annual deaths for tuberculosis in the ge ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of the RXR agonist IRX4204 to treat Multiple Sclerosis and other Immu

    SBC: IO THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Io Therapeutics is developing a novel agonist for the Retinoid X Receptors (RXR), IRX4204, to treat multiple sclerosis (MS) and other autoimmune diseases. RXR is a key nuclear receptor involved in inflammation. It has arole in regulating immunity through the enhancement of Treg activities and suppression of inflammatory Th17 activities. Because of the importanc ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Elastase Inhibition as a Novel Therapeutic Approach for Neuromyelitis Optica

    SBC: ANVIL BIOSCIENCES LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Neuromyelitis Optica (NMO) is a rare autoimmune inflammatory disease that affects the spinal cord and optical nerves leading to limb paralysis and loss of vision. Despite advances in the understanding of underlying disease mechanisms and patient diagnostic criteria there is a lack of treatment options. A specific cellular component of NMO disease was found to ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government